Oxcarbazepine: a review

Oxcarbazepine: a review

Oxcarbazepine recently gained a licence in the UK and USA. The purpose of this article is to review the pharmacology and therapeutics of oxcarbazepine for those prescribers unfamiliar with this interesting new antiepileptic drug1–3. Although only newly licensed in the UK and USA, oxcarbazepine has in fact been in routine clinical use in Denmark and other countries for up to 10 years, and experi...

Oxcarbazepine for refractory epilepsy: systematic review of the literature.

CONTEXT AND OBJECTIVE It has been estimated that 50 million people worldwide suffer from epilepsy and around 30% will not achieve adequate control over the disease. The aim was to evaluate the effectiveness of oxcarbazepine for refractory partial or generalized epilepsy. METHODS Systematic review. A search was conducted in the PubMed, Lilacs, EMBASE and CENTRAL databases. Studies were analyze...

Clinical recommendations for oxcarbazepine

Oxcarbazepine (OXC) is indicated for treating partial-onset with or without secondary generalized tonic-clonic seizures, in both adults and children aged over 6 years, as monotherapy or adjuvant therapy. Trials data and extensive clinical experience demonstrate generally good tolerability and antiepileptic efficacy similar to carbamazepine (CBZ), sodium valproate or phenytoin. Since the UK laun...

Crystal polymorphism in a carbamazepine derivative: oxcarbazepine.

Although crystal polymorphism of carbamazepine (CBZ), an anticonvulsant used to treat epilepsy, has been known for decades, the phenomenon has only recently been noted for its keto-derivative oxcarbazepine (OCB). Here it is demonstrated that OCB possesses at least three anhydrous polymorphs. Although all forms are morphologically similar, making differentiation between crystal modifications by ...

Oxcarbazepine Induced Hyponatremia: a Potential Explanation of Its Physiopathology